Alemtuzumab CARE-MS II 5-year follow-up Efficacy and safety findings

Alasdair J. Coles*, Jeffrey A. Cohen, Edward J. Fox, Gavin Giovannoni, Hans-Peter Hartung, Eva Havrdova, Sven Schippling, Krzysztof W. Selmaj, Anthony Traboulsee, D. Alastair S. Compston, David H. Margolin, Karthinathan Thangavelu, Madalina C. Chirieac, Darlene Jody, Panos Xenopoulos, Richard J. Hogan, Michael A. Panzara, CARE-MS II CAMMS03409, Raymond Hupperts, Douglas L. Arnold

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1117-1126
Number of pages10
JournalNeurology
Volume89
Issue number11
DOIs
Publication statusPublished - 12 Sep 2017

Keywords

  • REMITTING MULTIPLE-SCLEROSIS
  • CONTROLLED PHASE-3 TRIAL
  • BRAIN ATROPHY
  • INTERFERON BETA-1A
  • DISEASE-ACTIVITY
  • THYROID-CANCER
  • NATALIZUMAB
  • FINGOLIMOD
  • THERAPY
  • SWITCH

Cite this

Coles, A. J., Cohen, J. A., Fox, E. J., Giovannoni, G., Hartung, H-P., Havrdova, E., Schippling, S., Selmaj, K. W., Traboulsee, A., Compston, D. A. S., Margolin, D. H., Thangavelu, K., Chirieac, M. C., Jody, D., Xenopoulos, P., Hogan, R. J., Panzara, M. A., CARE-MS II CAMMS03409, Hupperts, R., & Arnold, D. L. (2017). Alemtuzumab CARE-MS II 5-year follow-up Efficacy and safety findings. Neurology, 89(11), 1117-1126. https://doi.org/10.1212/wnl.0000000000004354